Skip to content
Precision for Medicine
Press Release

Precision Medicine Group joins McKesson's Oncology & Multispecialty segment. Read more in McKesson Business Highlights.

ARM survery_Gated page_Hero_Resized

Survey Report

What’s Next for Cell and Gene Therapy: CGT Executive Perspectives

Obstacles and opportunities for the industry, from the point of view of those leading it

 
Survey Report

Cell and Gene Therapy Trends Survey: How CGT Leaders See the Future

Cell and gene therapy has entered a new phase of maturity, and to better understand how industry leaders are navigating this shift, Precision for Medicine and Precision AQ partnered with the Alliance for Regenerative Medicine (ARM) to survey nearly 50 cell and gene therapy executives across the industry.

The findings reveal what barriers remain, where organizations are investing, and the strategies shaping the next era of CGT development and commercialization.

The Consensus: Gene and Cell Therapy is Entering its Execution Era

Across the board, CGT executives agreed that the question is no longer “will the therapy work?” but rather “will it sell?”, with discussion centered upon:

  • Building confidence in the predictable application of regulatory policy
  • Barriers to adoption and what organizations are doing to expand patient access
  • Addressing delivery constraints alongside increasing competitive pressures

Download the report to see the full survey findings and how they provide a blueprint for every cell and gene therapy developer’s next chapter.

ARM CGT Survey Report Thumbnail

Download the Survey Report

arm-survey-presentation-video-highlights

Bonus Content: Hear Expert Perspectives

Precision's Dr. Harpreet Singh joined Dr. Seth Ettenberg, President and CEO of BlueRock Therapeutics, for a Spotlight Presentation on these survey findings during the 2026 Cell & Gene Meeting on the Mesa.

You’ll find videos embedded throughout the report with highlights from their discussion on the implications of key results.

Curated Insights

Stay ahead with the latest insights in cell and gene therapy innovation from our experts.